The indication applies to adults with type 2 diabetes and established cardiovascular disease, with the decision based on SURPASS-CVOT trial results.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.